MedTrace Logo

Efficacy of Topotecan and Lapatinib in Early Recurrent Ovarian or Peritoneal Cancer

NCT00888810 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2009-04-28

No results posted yet for this study

Summary

The objective of the trial was to evaluate the efficacy of the association of topotecan and lapatinib in patients who failed first line platinum-based chemotherapy within 12 months.

Conditions

Interventions

DRUG

TOPOTECAN

IV administration on Day 1, day 8 and day 15, at the dose level of 3.2 mg/m² for 6 cycles of 28 days(up to 8 cycles)

DRUG

LAPATINIB

Daily oral administration during all the study. 1250 mg/day

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète

    collaborator OTHER

  • Centre Francois Baclesse

    lead OTHER

Principal Investigators

  • Florence JOLY, MD-PHD · Centre François Baclesse

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00888810 on ClinicalTrials.gov